Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2022-12-22 00:00:00 ET · period of report 2022-12-20 · accession 0000899243-22-039217 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $23.03 | +16.9K | 16.3K | New | +$389.8K |
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $29.15 | -16.9K | 0 | -100% | -$493.4K |
| DM | 2022-12-22 | 2022-12-20+ | VRDN | Meisner Lara | GC, Sec | M - OptEx | $0.00 | -16.9K | 44.7K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-20 | M | A | 600 | $23.03 | 600 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-20 | S | D | 600 | $28.07 | 0 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-12-21 | M | A | 16,326 | $23.03 | 16,326 | D | — | — | |
| 4 | Common | Common Stock | 2022-12-21 | S | D | 16,326 | $29.19 | 0 | D | — | — | (F2) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-12-20 | M | D | 600 | $0.00 | 61,047 | D | $23.03 · — to 2031-09-22 | 600 Common Stock | (F3) The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-12-21 | M | D | 16,326 | $0.00 | 44,721 | D | $23.03 · — to 2031-09-22 | 16,326 Common Stock | (F3) The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |